Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Rapid PCR-based diagnosis of superficial mycoses with ROC-optimized cutoffs.

Created on 14 Aug 2026

Authors

Yuyuan Xue, Mingjing Wei, Yuhang Mei, Xindi Ma, Li Li, Junhao Zhu, Guo Chen, Min Zhu

Published in

Microbiology spectrum. Pages e0135726. Aug 14, 2026. Epub Aug 14, 2026.

Abstract

Fluorescence microscopy and fungal culture are the primary diagnostic methods for superficial fungal infections, but they are limited by low sensitivity and long turnaround time, respectively. We determined the optimal cycle threshold (Ct) cutoff for a novel multiplex PCR assay (iFIND) using receiver operating characteristic analysis and evaluated whether a "microscopy + iFIND" combined strategy improves diagnostic performance. This prospective study enrolled 113 patients with suspected superficial mycoses. Specimens underwent fluorescence microscopy, fungal culture, and automated iFIND. Using a composite reference standard, we calculated positive percent agreement (PPA), negative percent agreement, and overall percent agreement. Cohen's kappa and McNemar's test assessed inter-method agreement. To mitigate verification bias, we performed a sensitivity analysis excluding cases diagnosed solely by clinical response. Internal bootstrap validation (1,000 resamples) was used to assess overfitting of the Ct cutoff. The optimal Ct cutoff for any fungal infection was 32.66 (area under the curve [AUC] = 0.746). Bootstrap validation confirmed robustness (optimism-corrected AUC = 0.7431, optimism = 0.00275, bias-corrected and accelerated 95% confidence interval for cutoff: 32.5-33.7). iFIND showed excellent discrimination for Epidermophyton (AUC = 0.824) and Trichophyton (AUC = 0.834). The combined approach achieved a PPA of 65.6%, superior to microscopy alone (50.0%, P < 0.001) and comparable to culture (75.0%, P = 0.701), while reducing turnaround time from weeks to <3 h. Sensitivity analysis excluding 15 clinically diagnosed cases yielded consistent results: iFIND alone PPA = 46.9% (23/49), combined strategy PPA = 69.4% (34/49). iFIND detected an additional 17.2% of infections missed by conventional methods. The iFIND assay is a rapid, accurate tool for superficial mycoses. The microscopy + iFIND strategy combines speed and sensitivity, offering culture-comparable utility with substantially faster results. However, positive results should be interpreted in a clinical context to avoid overtreatment.
Fungal skin infections affect one in four people worldwide, but current diagnostic methods are either insensitive (microscopy) or painfully slow (culture, taking 2-4 weeks). This study validates a rapid PCR test that delivers results in under 3 h and, when combined with microscopy, matches the accuracy of culture. By establishing a data-driven cutoff value for test positivity and using rigorous statistical methods to confirm its reliability, we provide a practical framework that clinics can adopt immediately. The combined strategy reduces diagnostic delay, enabling same-day treatment decisions and reducing unnecessary antibiotic use. This is especially critical, given the global spread of antifungal-resistant strains, where rapid genus-level identification can guide appropriate therapy and curb resistance. Our approach offers an actionable, culture-comparable solution for routine clinical practice, directly addressing the urgent need for faster, more accurate fungal diagnostics worldwide.

PMID:
42599092
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement